BioEngine joyfully celebrates its tenth anniversary.

On December 24th, 2024, BioEngine welcomed its tenth anniversary. This moment of great significance was grandly launched in both Pujiang and Jinshan of Shanghai. The senior management team and employees from the two places gathered together. There were wonderful entertainment activities, and the scene was filled with laughter and joy. Pride and happiness were written on everyone's face, creating a warm and lively atmosphere.

On the occasion of this tenth anniversary, the corporate culture wall also made a wonderful appearance, displaying the company's values, vision, goals, important milestones and glorious achievements. It will become a lighthouse that inspires and guides employees in their daily work, enabling everyone to be full of confidence and expectation and work together to create more glories.

Professor Tan Wensong, the founder and chairman of BioEngine, took the lead in giving a speech: "Over the past ten years, BioEngine has gone through a proud decade by relying on technological leadership, service-driven efforts and quality assurance. Every member of BioEngine is the company's greatest wealth. It has always been our unwavering pursuit to keep doing the difficult but right things and to bring BioEngine's achievements to benefit people's health. We believe that BioEngine will shine even more brightly in the future!"

Dr. Liu Xuping, the president of BioEngine, said, "The past ten years have been a decade of passionate struggle for BioEngine. We have achieved a number of project achievements that are 'the first in China' and 'the world's first', and cultivated a group of talents in the field of biomedical cell culture. In the future, we will continue to strive forward and bring high-quality products to our customers and the market."

During the ten-year development process, we have achieved many important milestones, which have shaped our identity and reputation.

From 2014 to 2016,BioEngine was established in Shanghai. The application service platform for antibody and vaccine biomanufacturing technologies was set up. The first antibody fusion protein drug in China that applied domestic culture medium formulations and processes was launched on the market. The world's first serum-free high-density suspension culture technology for MDCK cells was used in the industrial production of avian influenza vaccines.

From 2017 to 2019,It became the first cell culture medium enterprise in China to pass the ISO 13485 (EU) quality system certification (BSI). The first serum-free culture medium for immune cells in China was applied to cell therapy clinical trial projects. The independently developed AI-based culture medium development and culture process optimization platform was completed, and multiple products were launched on the market one after another.

From 2020 to 2022,The Phase II of the production and manufacturing base was completed and put into use, with the maximum batch production capacity of 100,000 liters (3 tons) of serum-free culture medium. It obtained the ISO 13485:2016 and MDSAP (FDA) quality system certifications. It supported the first project in China to produce rabies virus vaccines based on the serum-free culture process of Vero cells. It took the lead in compiling the first group standard for animal cell serum-free culture medium in China.

From 2023 to the present,The headquarters and R&D center were relocated to Pujiang, opening a new chapter in development.